Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus

详细信息查看全文

作者：G. Ralph Corey^a ; Francis F. Arhin^b ; Matthew A. Wikler^c ; ¹ ; Daniel F. Sahm^d ; Barry N. Kreiswirth^e ; José ; R. Mediavilla^e ; Samantha Good^c ; ² ; Claude Fiset^c ; Hai Jiang^c ; ³ ; Greg Moeck^b ; ^{greg.moeck@themedco.com" class="auth_mail" title="E-mail the corresponding author} ; Heidi Kabler^f ; Sinikka Green^g ; William O'Riordan^h ; on behalf of the SOLO I ; SOLO II Investigators
关键词：Acute bacterial skin infection ; Single-dose treatment ; Clinical efficacy ; MRSA ; Lipoglycopeptide ; Phase 3 study
刊名：International Journal of Antimicrobial Agents
出版年：2016
出版时间：November 2016
年：2016
卷：48
期：5
页码：528-534
全文大小：274 K

文摘

•: Phase 3 acute bacterial skin and skin-structure infection (ABSSSI) studies SOLO I and SOLO II included 405 patients with confirmed MRSA.
•: Clinical response rates by pathogen were similar for oritavancin and vancomycin.
•: Clinical response in Staphylococcus  aureus patients was not impacted by spa type or pvl gene.
•: Oritavancin exhibited potent in vitro activity against all baseline pathogens.
•: Oritavancin provides a single-dose alternative to multidose vancomycin for ABSSSI.